Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT)
Buckanovich, R. J., Berger, R., Sella, A., Sikic, B. I., Shen, X., Ramies, D. A., Smith, D. C., Vergote, I. B.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
Antitumor activity observed in a phase I drug–drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC)
Choueiri, T. K., Pal, S. K., Cabanillas, M. E., Ramies, D. A., Tseng, L., Holland, J. S., Morrissey, S., Dutcher, J. P.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy
Blum, K. A., Smith, M., Fung, H., Zalevsky, J., Combs, D., Ramies, D. A., Younes, A.
Published in Journal of clinical oncology (20.05.2009)
Published in Journal of clinical oncology (20.05.2009)
Get full text
Journal Article
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
EBERHARD, David A, JOHNSON, Bruce E, KLEIN, Pam, MILLER, Vincent A, OSTLAND, Michael A, RAMIES, David A, SEBISANOVIC, Dragan, STINSON, Jeremy A, ZHANG, Yu R, SESHAGIRI, Somasekar, HILLAN, Kenneth J, AMLER, Lukas C, GODDARD, Audrey D, HELDENS, Sherry L, HERBST, Roy S, INCE, William L, JÄNNE, Pasi A, JANUARIO, Thomas, JOHNSON, David H
Published in Journal of clinical oncology (01.09.2005)
Published in Journal of clinical oncology (01.09.2005)
Get full text
Journal Article
Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer
HERBST, Roy S, JOHNSON, David H, HONG, Waun K, TRAN, Hai, TSAO, Anne, DONG XIE, RAMIES, David A, MASS, Robert, SESHAGIRI, Somasekar, EBERHARD, David A, KELLEY, Sean K, SANDLER, Alan, MININBERG, Eric, CARBONE, David P, HENDERSON, Ted, KIM, Edward S, BLUMENSCHEIN, George JR, LEE, Jack J, LIU, Diane D, TRUONG, Mylene T
Published in Journal of clinical oncology (10.04.2005)
Published in Journal of clinical oncology (10.04.2005)
Get full text
Journal Article
Conference Proceeding
Independent review of fatal interstitial lung disease (ILD) in TRIBUTE: paclitaxel + carboplatin ± erlotinib in advanced non-small cell lung cancer (NSCLC)
Gandara, D. R., Yoneda, K., Shelton, D., Beckett, L. A., Ramies, D. A., Bloss, J., Herbst, R. S.
Published in Journal of clinical oncology (20.06.2006)
Published in Journal of clinical oncology (20.06.2006)
Get full text
Journal Article
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): Early termination due to increased toxicities
MESSERSMITH, Wells A, LAHERU, Daniel A, SENZER, Neil N, DONEHOWER, Ross C, GROULEFF, Paula, ROGERS, Theresa, KELLEY, Sean K, RAMIES, David A, LUM, Bert L, HIDALGO, Manuel
Published in Clinical cancer research (01.10.2004)
Published in Clinical cancer research (01.10.2004)
Get full text
Journal Article
P1-17-10: Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Trial
Tolaney, SM, Nechushtan, H, Berger, R, Kurzrock, R, Ron, IG, Schöffski, P, Awada, A, Yasenchak, CA, Burris, HA, Ramies, DA, Shen, X, Winer, EP
Published in Cancer research (Chicago, Ill.) (15.12.2011)
Published in Cancer research (Chicago, Ill.) (15.12.2011)
Get full text
Journal Article